Denali Therapeutics stock gets stronger AVLAYAH outlook
Published on 11/17/2026 at 22:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDenali advances commercial and pipeline plans
- AVLAYAH revenue reached about 18 million US dollars in the third quarter, above prior guidance of 10 million to 12 million US dollars.
- Management expects Sanfilippo Type A data in February 2027 and Alzheimer's program data during 2027.
- Denali aims to become the Hunter syndrome market leader in 2027.
Denali Therapeutics used the UBS Global Biopharma Conference on Tuesday, November 17, 2026, to outline faster-than-expected adoption of AVLAYAH and a broader commercial strategy for its TransportVehicle platform. The company raised fourth-quarter AVLAYAH revenue guidance to 30 million to 32 million US dollars, according to Investing.com.
Commercial launch gains traction
Management said AVLAYAH revenue reached about 18 million US dollars in the third quarter, above prior guidance of 10 million to 12 million US dollars. Faster payer access and earlier transitions from the expanded access program supported the launch, while about 95% of current patients switched from Elaprase.
Denali said it believes it can become the market leader in Hunter syndrome in 2027. The company estimates that 375 of roughly 500 US patients with Hunter syndrome are eligible under the current FDA label.
Pipeline milestones extend into 2027
The company said pivotal Sanfilippo Type A data are expected at the WORLDSymposium in February 2027, after completion of the 49-week study in September. Denali plans to use the data to support a biologics license application, with manufacturing preparations forming part of the filing timetable.
Denali also expects data from its tau and A-beta Alzheimer's programs in 2027. The COMPASS confirmatory study for AVLAYAH is expected to reach its two-year endpoint for all patients by the end of 2027, with results targeted for the first half of 2028.
Latest Lang and Schwarz quote
Denali Therapeutics stock traded at 16.38 euros on Lang & Schwarz at 10:16 p.m. CET on Tuesday, November 17, 2026.
Denali Therapeutics Inc.
- ISIN: US24823R1059
- Ticker: DNLI
- Home exchange: Nasdaq
- Lang and Schwarz quote: 16.38 euros at 10:16 p.m. CET on November 17, 2026
The broader US market context is available through the Nasdaq Composite.
